Female | Age
Item
1. women aged 18 to 70 years old.
boolean
C0086287 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Previous diagnosis of breast cancer
Item
2. has a previous diagnosis of breast cancer (ductal or lobular carcinoma, invasive).
boolean
C0678222 (UMLS CUI [1,1])
C0262926 (UMLS CUI [1,2])
A date of diagnosis of breast cancer
Item
3. 1 year from diagnosis of breast cancer.
boolean
C0678222 (UMLS CUI [1,1])
C2316983 (UMLS CUI [1,2])
Stable heterosexual relationship
Item
4. stable heterosexual partnership =/>5 years or by investigator discretion.
boolean
C0205360 (UMLS CUI [1,1])
C0556476 (UMLS CUI [1,2])
Duration of dyspareunia
Item
5. more than 6 months of consistent insertional pain with intercourse (may have stopped having intercourse due to this consistent experience of pain).
boolean
C1384606 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Menopause status demonstrated by following criteria:
Item
6. menopausal, demonstrated by at least one of the following:
boolean
C3829127 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
C0332282 (UMLS CUI [1,3])
Cessation of menses | Bilateral oophorectomy | Follicle stimulating hormone (fsh) level in women below age 50 with an ovary and scarred or absent uterus
Item
i. cessation of menses for 1 years ii. bilateral oophorectomy iii. follicle stimulating hormone (fsh) level >25 in women below age 50 with an ovary and scarred or absent uterus (acceptable fsh levels can be inferred if the woman's oncologist monitors fsh during aromatase inhibitor therapy).
boolean
C0002453 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0278321 (UMLS CUI [2])
C0202022 (UMLS CUI [3,1])
C0001779 (UMLS CUI [3,2])
C0086287 (UMLS CUI [3,3])
C0029939 (UMLS CUI [3,4])
C0150312 (UMLS CUI [3,5])
C0042149 (UMLS CUI [3,6])
C0241158 (UMLS CUI [3,7])
C0202022 (UMLS CUI [4,1])
C0001779 (UMLS CUI [4,2])
C0086287 (UMLS CUI [4,3])
C0029939 (UMLS CUI [4,4])
C0150312 (UMLS CUI [4,5])
C0425913 (UMLS CUI [4,6])
Willingness to enter a study comparing a topical placebo liquid to topical liquid lidocaine.
Item
7. willingness to enter a study comparing a topical placebo liquid to topical liquid lidocaine.
boolean
C2348568 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
C0023660 (UMLS CUI [2,1])
C0032042 (UMLS CUI [2,2])
C0302908 (UMLS CUI [2,3])
C1522168 (UMLS CUI [2,4])
C1707455 (UMLS CUI [2,5])
Willing to evaluate the liquids by use of a tampon test | Willing to attempt an intercourse if the tampon test indicates tolerable penetrative pain
Item
8. willingness to evaluate the liquids by use of a tampon test as many as 4 times per month, and willingness to attempt intercourse if the tampon test indicates tolerable penetrative pain.
boolean
C0302908 (UMLS CUI [1,1])
C1704612 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,3])
C0600109 (UMLS CUI [1,4])
C0009253 (UMLS CUI [2,1])
C0600109 (UMLS CUI [2,2])
C0030193 (UMLS CUI [2,3])
C4053931 (UMLS CUI [2,4])
Benign phyllodes tumor of the breast | Malignant phyllodes tumor of the breast
Item
1. diagnosis of benign or malignant phyllodes tumor of the breast.
boolean
C0334501 (UMLS CUI [1])
C0010701 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C0006141 (UMLS CUI [2,3])
Deep dyspareunia
Item
2. consistently has pain in the pelvis or low abdomen during or after intercourse (deep dyspareunia).
boolean
C1384606 (UMLS CUI [1,1])
C0205125 (UMLS CUI [1,2])
Stricture of vagina to the point of being unable to succeed in having vaginal penetration | Physical examination
Item
3. has developed shrinkage of the vaginal opening or vaginal length to the point of being too small to succeed in having vaginal penetration with the partner (will also be assessed at the clinical exam).
boolean
C0269208 (UMLS CUI [1,1])
C0556623 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C0031809 (UMLS CUI [2])
Partner has a problem of sexual dysfunction
Item
4. partner has a problem of sexual dysfunction limiting his performance or making it inconsistent.
boolean
C0036911 (UMLS CUI [1,1])
C0549622 (UMLS CUI [1,2])
Serious current medical condition of a patient or her partner that might interrupt a study
Item
5. the potential subject or her partner has a serious current medical condition that might interrupt completion of a 6 month study.
boolean
C3843040 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
C0682323 (UMLS CUI [2,1])
C3843040 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
C0439801 (UMLS CUI [2,4])
Pelvic floor myalgia
Item
6. potential subject has been diagnosed by a physical therapist with significant pelvic floor muscle dysfunction causing pain (pelvic floor myalgia).
boolean
C4076753 (UMLS CUI [1])
Recent use of topical estrogen | Recent use of systemic estrogen
Item
7. potential subject has used topical or systemic estrogen within the last 4 months.
boolean
C3541386 (UMLS CUI [1,1])
C1522168 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C3541386 (UMLS CUI [2,1])
C1515119 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
Tenderness of vestibule mucosa immediately after application of both test liquids
Item
8. has continued tenderness of vestibule mucosa immediately after application of both test liquids.
boolean
C0185125 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
C0227765 (UMLS CUI [1,3])
C0234242 (UMLS CUI [1,4])
Lidocaine hypersensitivity | Hypersensitivity to local anaesthetics
Item
9. allergy to lidocaine or other numbing agents.
boolean
C0023660 (UMLS CUI [1,1])
C0020517 (UMLS CUI [1,2])
C0002934 (UMLS CUI [2,1])
C0020517 (UMLS CUI [2,2])